The available low molecular weight heparin preparations are not the same

Clinical and Applied Thrombosis/Hemostasis

Volumn 3, Issue 1 SUPPL., 1997, Pages

  Fareed, Jawed ^a   Hoppensteadt, Debra ^a   Jeske, Walter ^a   Clarizio, Rana ^a   Walenga, Jeanine M ^a   Bick, Rodger L ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antithrombin; LMW heparin; TFPI; Thromboembolic diseases; Thrombosis prophylaxis

Indexed keywords

EID: 0002981417     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029697003001s07     Document Type: Article

References (46)

1. Fareed J., Walenga JM, Kumar A., Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemost 1985; 11:155.
2. Fareed J., Hoppensteadt D., Huan X., Racanelli A. Comparative study on the in vitro and in vivo activities of seven low molecular weight heparins. Hemostasis 1989;18(suppl 3):3.
3. Abildgaard U, Sandset P, Lindahl A. Tissue factor pathway inhibitor. In: Poller L, ed. Recent advances in blood coagulation. Edinburgh, U.K.: Churchill Livingstone, 1993:105-24.
4. Broze GJ Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinol 1995;6:S7.
5. Van Dedem G, Nielsen JI Determinations of the molecular mass of low molecular mass (LMM) heparin. Pharmeuropa 1991;3: 202-18.
6. Fareed J., Walenga JM, Lassen M., Borris L., Hoppensteadt DA Pharmacologic profile of a low molecular weight heparin (Enoxaparin): Experimental and clinical validation of the prophylactic antithrombotic effects. Acta Chir Scand 1990;156(suppl 556):75.
7. Cade JF, Buchanan MR, Boneu B., Ockelford P. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the preparation. Thromb Res 1984;35:613.
8. Fareed J., Kumar A., Rock A., Walenga JM, Davis P. A primate model (Macaca mulatta) to study the pharmacokinetics of heparin and its fractions. Semin Thromb Hemost 1985; 11:138.
9. Raake W., Elling H. Rat jugular vein hemostasis-a new model for testing antithrombotic agents. Thromb Res 1989;53:73-7.
10. Barrowcliffe TW Annotation: Low molecular weight heparins. Bi-J Hematol 1995;90:1.
11. Luldahl AK, Abilgaard U., Larsen ML, Aamodt LM, Nordfang O., Beck TC Extrinsic pathway inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin-induced coagulation. Thromb Res 1991;64:155.
12. Abildgaard U. Relative role of tissue factor pathway inhibitor and antithrombin in the control of thrombogenesis. Blood Coagul Fibrinol 1995;6:545.
13. Broze GJ Jr.Tissue factor pathway inhibitor and the current concept of blood coagulation. Blood Coagul Fibrinol 1995;6:S7.
14. Hoppensteadt DA, Jeske W., Fareed J., Bermes EW Jr.The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low molecular weight heparin. Blood Coagul Fibrinol 1995; 6:S57.
15. Bognacki J., Hammelburger J. Functional and immunologic methods for the measurement of human tissue factor pathway inhibitor. Blood Coagul Fibrinol 1995;6:S65.
16. Lindahl AK, Sandset PM, Abilcigaard U. The present status of tissue factor pathway inhibitor. Blood Coagul Fibrinol 1992;3:439.
17. Petersen CC, Bjorn SE, Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb Haemost 1991; 67:537.
18. Jeske W., Hoppensteadt D., Klausen R.,et al.Effect of repeated aprosulate and enoxaparin administration on TFPI antigen levels. Blood Coagul Fibrinol 1995;6: 119.
19. Hoppensteadt D., Walenga JM, Fasanella A., Jeske W., Fareed J. TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin. Thromb Res 1995;77:175.
20. Fareed J. Basic and applied pharmacology of low molecular weight heparins. Pharm Ther 1995;16s-24s.
21. Fareed J., Walenga JM, Pifarre R. Newer approaches to the pharmacologic management of acute myocardial infarction. Cardiac Surg 1992;6:101.
22. Fareed J., Callas D., Hoppensteadt D., Jeske W., Walenga JM Recent developments in antithrombotic agents. Invest Exp Opin Drugs 1995;4:389-412.
23. Fareed J., Walenga JM, Hoppensteadt DA, Racanelli A., Coyne E. Chemical and biochemical heterogeneity in low molecular weight heparins: Implications for clinical use and standardization. Semin Thromb Hemost 1989; 15:440.
24. Fareed J., Callas D., Hoppensteadt D., Jeske W., Walenga JM Recent developments in antithrombotic agents. Exp Opin Invest Drugs 1995;4:389.
25. Fareed J., Walenga JM, Pifarre R. Newer approaches to the pharmacologic management of acute myocardial infarction. Cardiac Surgery: State of the Art Reviews 1992;6: 101.
26. Hirsh J., Siragusa S., Cosmi B., Ginsberg JS Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995; 74:360-363.
27. Hanke H., Oberhoff M., Hanke S.,et al.Inhibition of cellular proliferation after experimental balloon nogioplasty by low molecular weight heparin. Circulation 1992;85:1548.
28. Schmid KM, Preisack M., Voelken W. Sujatta M. Karsch KR First clinical experience with low molecular weight heparin LU 47311 (Reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Hemost 1993;19:155.
29. Kakkar VV Effectiveness and safety of low molecular weight heparins (LMWH) in the prevention of venous thromboembolism (VTE), Thromb Haemostas 1995;74:368.
30. Fareed J, Hoppensteadt D, Walenga JM. A perspective on low molecular weight heparins in the management of thrombosis. Haemostaseologie 1993;13:S5.
31. Differentiation of beef and pig mucosal heparins by NMR spectroscopy [Letter]. Thromb Haemostast 1995;74.1197-207.
32. Fareed J., Hoppensteadt D., Lyer L. Impact of biotechnology in the diagnostic and therapeutic management of cardiovascular disorders. In: Longnecker JB, ed. Nutrition and biotechnology in heart disease and cancer. New York: Plenum Press, 1995:99-110.
33. Fareed J., Callas D., Hoppensteadt D., Jeske W., Walenga JM Recent developments in antithrombotic agents. Exp Opin Invest Drugs 1995;4:389.
34. Agnelli G., Iorlo A., Renga C., Boschetti E., Nenci GG, Ofosu FA Prolonged antithrombin activity of low molecular weight heparins. Clinical implications for the treatment of thromboembolic diseases. Circulation 1995;92:2819-24.
35. Raskob GE Low molecular weight heparin for the prevention and treatment of venous thromboembolism. Curr Opin Pulmonary Med 1996;2:305-10.
36. Fareed J., Walenga JM, Hoppensteadt D., Huan X., Nonn R. Biochemical and pharmacologic inequivalence of low molecular weight heparins. Ann NY Acad Sci 1989;556:333-53.
37. Fareed J., Callas DD, Hoppensteadt D., Jeske W., Walenga JM Recent developments in antithrombotic agents. Exp Opin Invest Drugs 1995;4:389-412.
38. Brieger D., Dawes J. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins. Thromb Haemost 1997;77:317-22.
39. Collignon F., Frydman A., Caplain H.,et al.Comparison of the pharmacokinetie profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995;73:630-40.
40. Eriksson BI, Söderberg K., Widlund L., Wandeli B., Tengbom L., Risberg B. A comparative study of three low-molecular weight beparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995;73:398-401.
41. Boneu B. Low molecular weight heparin therapy: Is monitoring needed? Thromb Haemost 1994;72:330-4.
42. Samama M. Contemporary laboratory monitoring of low molecular weight heparins. Thromb Haemost 1995;15:119-23.
43. Hoppensteadt DA, Jeske W., Fareed J. Laboratory monitoring of new anticoagulant and antithrombotic drugs. In: Pifarré R, ed. New anticoagulants for the cardiovascular patient. Philadelphia: Hanley & Belfus, 1997:521-38.
44. Hawkins DW Global economic perspective on the use of low molecular weight heparin. Clin Appl Thromb Hemost 1996;2(suppl 1): S40-3.
45. Hull RD, Feldstein W., Stein PD, Pineo GF Cost-effectiveness of pulmonary embolism diagnosis. Arch Intern Med 1996; 156:68-78.
46. Hirsh J., Raschke R., Warkentin TE, Dalen JE, Deykin D., Poller L. Chest 1995;108(suppl 4):258S-75S.